FrançaisAre analysts right about Corcept Therapeutics Incorporated (CORT)?
📈 See the interactive version (live chart) →
Historical analyst accuracy
For Corcept Therapeutics Incorporated, we replayed every analyst price target of the past 12 months and measured the real outcome: 56% were profitable, average return +38% (70 calls). At 3 months: +12% average return (48% profitable). The higher the %, the more often analysts were right on this stock.
Most reliable analysts on this stock (past track record)
Their past track record on this stock (targets replayed against real prices) — not a forecast of what will happen.
| Analyst / broker | Calls i | % profitable i | Avg return i |
|---|---|---|---|
| HC Wainwright & Co. | 24 | 54% | +41% |
| Canaccord Genuity | 11 | 64% | +31% |
| Piper Sandler | 10 | 50% | +29% |
| Truist Securities | 8 | 88% | +104% |
Frequently asked questions
Is Corcept Therapeutics Incorporated a buy right now?
The analyst consensus on Corcept Therapeutics Incorporated (CORT) is "Buy" (19 bullish, 1 bearish calls over 12 months). This is not advice: historically, 56% of their targets on this stock turned out profitable over 1 year.
What is Corcept Therapeutics Incorporated's price target?
The median 12-month price target is $161 (+87% vs $85.95), ranging from $50.00 to $165 (5 analysts).
Are analysts accurate on Corcept Therapeutics Incorporated?
Over 1 year, 56% of analyst targets on Corcept Therapeutics Incorporated were profitable, for an average return of +38% (across 70 timestamped calls). This is JPI Invest's accuracy metric.
What is the Corcept Therapeutics Incorporated stock forecast?
Analysts target a median of $161 within 12 months, i.e. +87% vs the current price. The most bullish targets $165, the most cautious $50.00.
What is the Corcept Therapeutics Incorporated stock forecast for 2026 or long term (2030)?
Note: analyst targets are 12-month (median $161, +87%), NOT 2030. No reliable 5-10 year price forecast exists (« 2030 prediction » models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (56%), and the stock's past trajectory.
Is Corcept Therapeutics Incorporated overvalued?
Detailed valuation data for Corcept Therapeutics Incorporated is available in the interactive analysis.
📊 See the full interactive analysis of Corcept Therapeutics Incorporated →
What is JPI Invest?
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best — on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
- 🏆 Analyst leaderboard by real reliability (beating their sector, not just riding the rally)
- 🎯 What to buy: 3 backtested methods over 6 years, from cautious to aggressive
- 💬 AI assistant: ask anything about any stock, with the numbers
- 📊 Portfolio tracking + 🔔 price alerts by email
⚠️ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.